- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TSCAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.04. | H.C. Wainwright bestätigt Kaufempfehlung für Tscan-Aktie mit Kursziel 7 US-Dollar | 4 | Investing.com Deutsch | ||
| 09.04. | H.C. Wainwright reiterates Buy on Tscan stock, $7 target | 3 | Investing.com | ||
| 02.04. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.03. | Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space | 1 | Insider Monkey | ||
| 04.03. | TScan Therapeutics GAAP EPS of -$0.18 beats by $0.06, revenue of $2.57M beats by $0.15M | 1 | Seeking Alpha | ||
| 04.03. | TScan Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 04.03. | TScan Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 04.03. | Earnings Breakdown: TScan Therapeutics Q4 | 1 | Benzinga.com | ||
| 04.03. | TScan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.02. | TScan schließt Patientenrekrutierung ab und erhält FDA-Zulassung für neue Krebstherapien | 2 | Investing.com Deutsch | ||
| 26.02. | TScan completes enrollment in trial cohort, receives FDA clearance | 1 | Investing.com | ||
| 26.02. | TScan Therapeutics, Inc.: TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 | 136 | GlobeNewswire (Europe) | Completed enrollment of Cohort C in the Phase 1 ALLOHA trial; patients to be treated with commercial-ready manufacturing process Received FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 targeting... ► Artikel lesen | |
| 12.01. | TScan Therapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 06.12.25 | TScan Therapeutics, Inc.: TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition | 209 | GlobeNewswire (Europe) | Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up... ► Artikel lesen | |
| 04.12.25 | TScan Therapeutics To Provide Update On Phase 1 Trial Of TSC-101 In Heme Malignancies Next Week | 1 | RTTNews | ||
| 03.12.25 | TScan Therapeutics lädt zu KOL-Event über aktualisierte ALLOHA-Studiendaten | 1 | Investing.com Deutsch | ||
| 03.12.25 | TScan Therapeutics, Inc.: TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA Phase 1 Trial and Future Market Opportunities | 2 | GlobeNewswire (USA) | ||
| 26.11.25 | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11.25 | Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials | 6 | Investing.com | ||
| 12.11.25 | Tscan Therapeutics: EPS übertrifft Schätzungen um 0,06 $ - Umsatz besser als erwartet | 1 | Investing.com Deutsch |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,15 | -0,28 % | Nahost-Konflikt belastet Märkte: Food-Lieferketten werden zum Schlüsselthema - MustGrow, K+S, Evotec und BioNTech im Fokus | Der Nahost-Konflikt rückt die globalen Lieferketten erneut in den Fokus und erhöht den Druck auf sensible Versorgungswege. Besonders die Straße von Hormus bleibt dabei ein zentraler geopolitischer Risikofaktor... ► Artikel lesen | |
| MEDIGENE | 0,025 | -2,34 % | Medigene: Zurückziehung - 18.11.2025 | ||
| AMGEN | 297,45 | -0,30 % | Amgen Announces Retirement Of David M. Reese, Executive Vice President And Chief Technology Officer | Organizational Changes Further Emphasize Integration of Biology and Technology
THOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced... ► Artikel lesen | |
| BIOGEN | 160,54 | -0,21 % | Biogen To Acquire TJ Bio's Rights To Felzartamab In The Greater China Region | WESTON (dpa-AFX) - Biogen Inc. (BIIB) and TJ Biopharma have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio's exclusive rights to felzartamab in the Greater... ► Artikel lesen | |
| BIOFRONTERA | 2,520 | -0,79 % | PTA-AFR: Biofrontera AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Biofrontera AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Biofrontera... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 652,10 | -0,52 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 17.04.2026 -2- | The following instruments on XETRA do have their last trading day on 17.04.2026.Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 17.04.2026.ISIN Name US5719032022 Marriott International... ► Artikel lesen | |
| EDITAS MEDICINE | 2,870 | +4,36 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| GALAPAGOS NV | 24,700 | 0,00 % | Galapagos Enters Framework Agreement With Gilead In Connection With Ouro Deal | FOSTER CITY (dpa-AFX) - Galapagos (GLPG, GLPG.AS) has entered into a binding agreement with Gilead Sciences (GILD) in connection with Gilead's agreement to acquire all of the outstanding equity... ► Artikel lesen | |
| IMMATICS | 9,420 | -1,21 % | Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting | Houston, Texas and Tuebingen, Germany, April 21, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| AUTOLUS THERAPEUTICS | 1,360 | +3,03 % | Autolus Therapeutics plc: Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ONCOPEPTIDES | 0,122 | -1,54 % | Oncopeptides AB: Outcome in Oncopeptides' rights issue | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,870 | 0,00 % | Stifel reiterates Tango Therapeutics stock rating on combo potential | ||
| AVACTA | 0,865 | 0,00 % | Avacta Group PLC: Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION delivery platform | ||
| DERMATA THERAPEUTICS | 1,300 | 0,00 % | RBC Capital initiates Dermata Therapeutics stock at outperform | ||
| LYELL IMMUNOPHARMA | 23,700 | 0,00 % | Lyell Immunopharma, Inc: Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma | PiNACLE - H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator's choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell... ► Artikel lesen |
Das Unternehmen TSCAN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,215 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TSCAN THERAPEUTICS INC finden Sie auf Wallstreet Online.